NanoViricides (NNVC) achieves Positive Clinical Results for Lead anti-HIV Candidate
NanoViricides Inc. today announced that in a recent animal study, the company’s lead anti-HIV nanoviricide candidate demonstrated efficacy equivalent to a highly active anti-retroviral therapy (HARRT) drug cocktail, a combination therapy often recommended as initial therapy in humans with HIV. The study demonstrated that NanoViricides’ lead anti-HIV nanoviricide successfully reduced HIV levels and protected human T cells in a manner consistent with the HAART cocktail. The company said it believes its candidate differs from current components of HAART therapy on a cellular level that would complement and enhance various HAART regimens. While there is no cure for HIV, NanoViricides said…